MONTREAL & BOSTON–(BUSINESS WIRE)– Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, today announced it has successfully completed its Phase 2, first-in-patients, dose ranging, clinical study of THR-184 for the prevention of acute kidney injury (AKI) in at risk patients undergoing cardiac surgery (NCT01830920). In the study, there was a reduction in the incidence of AKI in patients treated with the highest dose and THR-184 was safe and well tolerated. The effect was observed across different definitions of AKI and was most prominent in patients with underlying chronic kidney disease (CKD), which is an important risk factor for AKI.
THR-184 is a proprietary, first-in-class peptide that activates the BMP pathway. Results from a broad set of preclinical studies showed THR-184 had protective effects in animal models of AKI, and in two Phase 1 clinical trials THR-184 was found to be safe and well-tolerated. THR-184 has been granted Fast Track designation for the prevention of AKI following cardiac surgery by the U.S. Food and Drug Administration (FDA).
AKI is the sudden loss of kidney function, and it affects more than 1.2 million people each year in the United States and an estimated 13.3 million worldwide. It occurs in different clinical situations and is particularly frequent in patients hospitalized for major surgery, including cardiac and/or vascular surgery, trauma, infection, cardiac disease or cancer. The prevention of AKI is estimated to have a market value in excess of $3.5B. AKI can lead to permanent reduction of kidney function and is also associated with an increased risk of death, extended hospitalization, and increased medical cost. There are currently no available therapies to prevent or treat AKI.
Thrasos is a privately-held, clinical-stage biotherapeutics company with three products in development for kidney disease: THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The Company believes that its technology underlying THR-184 will be broadly applicable as well to other types of major surgery where AKI is also a significant complication. Thrasos is headquartered in Montreal, Canada, with a U.S. office in Boston, Massachusetts. www.thrasos.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160229005651/en/
Thrasos Therapeutics, Inc.
Donald Notman, 857-317-4290
Michelle Linn, 508-362-3087
Source: Thrasos Therapeutics